Noah Banoub, a third year medical student, describes his journey into medicine and his choice of specialty. He recounted how MacTel type 2 went from being a diagnosis of exclusion without a therapy to ...

OT Roundup covers the optogenetics Nobel Prize, remigromig in DME with Veeral Sheth, MD, Stargardt disease and a total human ...

Eclipse Life Sciences reports that its biodegradable 6-month fluocinolone acetonide implant met its primary safety end point ...

Restoring sight after whole human eye transplant remains a long-term goal, and the optic nerve is the limiting factor, ...

At AAO 2026, Adam, MD, shares Yamane technique pearls, from docking the trailing haptic to preventing tilt and haptic ...

Alvotech and Advanz Pharma have submitted a European regulatory application for AVT29, a proposed biosimilar to high-dose ...

Jacque Duncan, MD, reviews phase 3 DRAGON data on oral tinlarebant for Stargardt disease and its mechanism-related visual ...

Innovation in therapeutics has a lot on the horizon, he said, but all of those drugs and innovations can only be delivered by ...

At AAO 2026, Michael T. Yen, MD, explained how at-home subcutaneous elegrobart could ease treatment burden in thyroid eye ...

In addition to the results, Roche also announced that the US Food and Drug Administration (FDA) has accepted the company’s ...

Ehsan Rahimy, MD, says most PRIMA serious adverse events occurred early, while vision gains held through 36 months.

Liza M. Cohen, MD, explains when to use CT vs MRI in thyroid eye disease and why to review images yourself.